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Edited by Barry HalliwellAbstract Immunosenescence is the consequence of the continu-
ous attrition caused by chronic antigenic stress. The most impor-
tant characteristics of immunosenescence (accumulation of
memory and eﬀector T cells, reduction of naive T cells, shrinkage
of T cell repertoire, reduction of the immunological space) are
compatible with this assumption. Immunosenescence can be ta-
ken as proof that the beneﬁcial eﬀects of the immune system, de-
voted to the neutralization of harmful agents early in life, become
detrimental late in life, in a period not foreseen by evolution. This
perspective could explain the mechanisms of the ageing process
as well as the pathogenesis of age-related diseases.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Immunosenescence is a recent phenomenon, related to the
extraordinary and linear improvements in survival and lifespan
that began around the 19th century and are still occurring. It is
possible to speculate that the role of immunosenescence was
indeed negligible in the past, when the human lifespan was
40–50 years, and that its impact on morbidity and mortality
has emerged in combination with the extension of lifespan
[1]. The changes associated with immunosenescence, such as
inﬂamm-ageing, shrinkage of the T cell repertoire and ﬁlling
up of the immunological space with memory/eﬀector cells,
are playing a more and more important role in the emergence
of a series of age-related pathologies, conditioning the present
epidemiology of old people [2].
The ageing of the immune system (IS) is not a random pro-
cess without rules or directions, but rather is subject to evolu-
tionary constraints [3]. The IS has been probably selected to
serve individuals living until reproduction. The trend of thymic
ontogenesis and involution likely supports this hypothesis [4].
Our ancestors lived until 30–50 years of age. Nowadays, the IS
must serve the soma of individuals living 80–120 years, an*Corresponding author. Fax: +39 861 211395.
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doi:10.1016/j.febslet.2005.02.055enormous amount of time longer than that predicted by evolu-
tionary forces. Therefore, old people have to cope with a life-
long antigenic burden encompassing several decades of
evolutionary unpredicted antigenic exposure. This chronic
antigenic stress and the subsequent inﬂammatory burden have
a major impact on survival and frailty. The quality of ageing
and the peculiar remodeling of the IS in more advanced age
are the results of the individual immunological history, which
therefore heavily inﬂuences both longevity and successful age-
ing [5]. Individual immunological history derives from the
interaction between genetic background and speciﬁc lifelong
antigenic burden [6,7]. This latter depends on historical period
where you live, on geography (poor/dirty or reach/hygienized
countries) and on social/economic status and education. In-
deed, since the genetic pool of humans remained almost con-
stant in the last century, the recent spectacular improvement
in survival can be largely attributed to improved life conditions
and hygiene [8].2. Chronic antigenic load
The most important characteristic of immunosenescence is
the ﬁlling of the immunological space with memory and eﬀec-
tor cells as a consequence of exposure to a variety of antigens.
The continuous attrition caused by clinical and sub-clinical
infections, as well as the continuous exposure to other types
of antigens (food, allergens), is likely responsible for the
chronic IS activation and inﬂammation [8,9]. Inﬂamm-aging,
i.e. the peculiar chronic inﬂammatory status which character-
izes ageing, is under genetic control and is detrimental for lon-
gevity [10,11]. This age-related chronic inﬂammatory activity,
leading to long term tissue damage, is related to mortality risk
from all causes in old persons. A wide range of age-related dis-
eases, such as neurodegeneration, atherosclerosis, diabetes,
osteoporosis and sarcopenia, among others, share an inﬂam-
matory pathogenesis [12–18]. Therefore, immunosenescence
and probably morbidity and mortality will be accelerated in
those subjects who are exposed to an extra burden of antigenic
load. The phenomenology of HIV+ patients after several years
of infection, shows striking similarities (regarding T cell subset
derangement, T cell clonal expansion and telomere shortening
of T cells) with that observed in aged people [19]. It is possible
to speculate that prolonged chronic infections other than HIV,
despite being less aggressive, can lead to similar results. Largeblished by Elsevier B.V. All rights reserved.
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tors for single epitopes of CMV and EBV, detected using tet-
ramer technology, are common in the elderly and are
associated with a loss of early memory cells, an increase of
highly diﬀerentiated CD8+ cells, a gradual reduction of the
immunological space and an immune risk phenotype (IRP)
predicting mortality [20,21]. Conversely, immunosenescence
will be delayed in those subjects who lived for most of their life
in clean environments in which exposure to persistent viral
infections and parasitic infections are minimized. This is ex-
actly what happened in the last century in the most economi-
cally developed countries in which medical care, vaccination,
and hygiene in food, water, and housing contributed to reduce
the antigenic load, the exhaustion of naive T cells, the ﬁlling of
the immunological space, and consequently the rate of immu-
nosenescence [22]. Quality and quantity of the lifelong anti-
genic load, conditioning inﬂamm-ageing, is a major
determinant of immunosenescence, aging rate and longevity,
as well as of quality of life in advanced ages.Fig. 1. The continuous attrition on the immune system caused by
repeated antigen stimulations (clinical and subclinical infections, food
antigens, allergens and self antigens) is responsible for the increase in
activated cells and proinﬂammatory cytokines. As a consequence, a
peculiar chronic inﬂammatory status (inﬂamm-ageing) characterizes
immunosenescence. Inﬂammation and the continuous production of
oxidative metabolism by-products exhert a lifelong evolutionary
pressure on the immune system, which undergoes a gradual remodeling
in the attempt to re-establish a new balance that assures survival.3. Oxidative damage
In addition to antigens, other important stressors which con-
tinuously impinge on our IS, as well as on the other cells of the
organism, are oxidative metabolism by-products, mainly reac-
tive oxygen species (ROS), as a consequence of the lifelong
respiratory burst. The increased ROS production and accumu-
lation during ageing induce damage to important cellular com-
ponents (lipidic membranes, enzymatic and structural proteins
and nucleic acids) [23]. ROS damage is counteracted by several
genetically controlled enzymatic and non-enzymatic antioxi-
dant defense systems, DNA repair enzymes and speciﬁc dam-
age-induced apoptotic processes. All these protective
mechanisms tend to become less eﬀective with increasing age
and as a consequence cells undergo a sort of oxidative stress
adaptation with age-related accumulation of senescent and
mutated cells, tissue dysfunctions and increased risk of tumors.
The p53 protein works to suppress the development of tu-
mours by aﬀecting how cells respond to damage (DNA repair
or, if it fails, apoptosis). The p53 gene also plays an important
role in cellular senescence. It appears that increasing p53 activ-
ity reduces the incidence of cancer, but concurrently increases
the ageing rate. A ﬁne equilibrium between the antineoplastic
and pro-aging characteristics of p53 may lead to the optimal
lifespan for an organism: too little p53 results in death from
cancer, whereas too much p53 leads to death by accelerated
ageing. Depending upon the balance of positive and negative
inﬂuences, cell proliferation can continue or senescence may
ensue. Therefore, ageing is an antagonistically pleiotropic
manifestation of evolutionary pressures to prevent malignant
transformation, perhaps in large part via the actions of p53
[24].4. Immune system remodeling
The eﬀects of the lifelong antigen stimulation and ROS pro-
duction on the IS are illustrated in Fig. 1. As a consequence of
ROS accumulation, cells become resistant to damage-induced
apoptosis and senescent/dysfuntional lymphocytes increase,whereas chronic antigenic load induces age-related increase
of activated immune cells and hyperproduction of proinﬂam-
matory cytokines, both contributing to determine IS remodel-
ing and inﬂamm-ageing [1,10].
The hypothesis of remodeling suggests that immunosenes-
cence is the net result of the continuous adaptation of the
body to the deteriorative changes occurring over time.
According to this hypothesis, body resources are continu-
ously optimized, and immunosenescence must be considered
a very dynamic process [12]. The main ﬁndings which char-
acterize the IS remodeling during senescence are illustrated
in Fig. 2.
An elderly IS becomes more and more predisposed to
chronic inﬂammatory reactions and is less able to respond to
acute and massive challenges by new antigens. A young IS
has to cope quickly and eﬃciently with acute immunological
challenges to assure survival and reaching of reproductive
age. Such reaction capability gradually burns out because of
the lifelong antigenic attrition. Moreover, lifelong antigenic
challenges and the increasing antigenic burden, determine a
condition of chronic inﬂammation, with increased lymphocyte
activation and proinﬂammatory cytokines [4].
Another important ﬁnding of immunosenescence is the de-
creased stress responsiveness. The unavoidable chronic overex-
posure to stressors determines an highly pathogenic sustained
activation of the stress–response system leading to a pro-
gressively reduced capacity to recover from stress-induced
modiﬁcations [5,22].
Fig. 2. The main ﬁndings which characterize the immune system
remodeling, peculiar of immunosenescence, could be interpreted as the
result of both lifelong antigenic load and genetically determined ability
of the immune system to adapt to and counteract the eﬀects of
repeated and chronic antigenic stimuli as well as the accumulation of
potentially harmful oxidative metabolism byproducts. In a certain
sense, it is the very physiological defense function of the immune
system that determines immunosenescence and paradoxically repre-
sents the main determinant of the most common age-related diseases
and a major determinant of the ageing rate.
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senescence and age-related diseases. Genome instability, driven
by oxidative damage, is a primary cause of normal aging [7].
Caloric restriction may extend life-span by attenuating the oxi-
dative stress caused by normal metabolism [1]. Organisms have
developed regulatory processes against ROS to implement sur-
vival, mainly detoxifying activities, DNA repair enzymes and
speciﬁc apoptotic mechanisms, which become less eﬃcient dur-
ing ageing [2]. The correlation between ROS accumulation and
oxidative damage on one hand and the rate of ageing and inef-
ﬁciency of mechanisms protecting from mitochondrial ROS
production on the other is extremely good.As a consequence of both inﬂamm-ageing and ROS hyper-
production, a subtle modulation of apoptotic mechanisms
intervenes during ageing [4]. Lymphocytes undergo two dif-
ferent kinds of apoptotic processes: activation-induced cell
death, peculiar of immune cells following antigenic stimula-
tion and clonal expansion, and damage-induced cell death,
a more generalized phenomenon in response to a variety of
cellular insults, mainly oxidative damage, and is particularly
important for preventing the onset of neoplastic proliferation.
The decreased sensitivity to damage-induced apoptosis, char-
acteristic of senescent cells, contributes to the accumulation
of dysfunctional lymphocytes and expanded clones of mem-
ory and eﬀector CD8+ T cells with a global reduction of
the immunological space and increased risk of infectious,
neoplastic and degenerative disorders. The increase of activa-
tion-induced cell death, in response to inﬂammation cyto-
kines, contributes to exhaustion of naive cells, decreased
clonal expansion capability, reduced T cell responsiveness
with decreased ability to mount strong immune responses
to acute antigenic challenges, and shrinkage of immunologi-
cal repertoire [5].
The shortage of telomeric DNA is a speciﬁc kind of DNA
aging used by the cell to count cell divisions and monitor the
degree of DNA damage. The progressive increase of telomere
shortening, although inﬂuenced by genetic factors and telome-
rase activity, is therefore the result of the individual replicative
and immunological history. There is a strong association be-
tween telomere length in blood and mortality in people aged
60 years or older [7,25,26].
The thymic input of virgin T cells progressively decreases
with ageing. Recently, a marker for newly generated T lym-
phocytes, possibly related to lymphoid mass, has been identi-
ﬁed in the amount of the remnants of T cell receptor
rearrangement excision circles (TREC) present in T cells.
TREC (similarly to what happens to telomeres) are markers
of the T cell replicative history, being progressively diluted
by successive rounds of cell division. As expected, the number
of TREC drastically decay with age in peripheral blood T lym-
phocytes [27].
The analysis of immunological changes during senescence
and age-related markers of chronic inﬂammation could
provide a window on the individual immunological history
as well as useful prognostic markers of morbidity and
mortality.5. Markers of inﬂamm-ageing
Cellular, serological and genetic markers of inﬂamm-ageing
are now becoming available. On the basis of longitudinal stud-
ies [28,29] an immune phenotype predicting morbility and
mortality, the so called ‘‘IRP’’, has been deﬁned [12]. The accu-
mulation of antigen experienced T cells is a major characteris-
tic of an aged IS [30,31]. An exhaustion of naive T cells occurs
in centenarians [32]. The depletion of virgin CD8+ T lympho-
cytes can be considered a reliable biomarker related to the risk
of death [33,34]. A combination of high CD8+ and low CD4+
T cells and CD19+ B cells, plus a poor T cell proliferation in
response to mitogens, is a good predictor of higher morbility
and mortality in old people [35].
Ageing is associated with increased circulating levels of
pro-inﬂammatory cytokines. Increased levels of inﬂammatory
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Parkinsons disease, atherosclerosis, type 2 diabetes, sarcope-
nia, functional disability and high mortality risk. Therefore,
through inﬂammation and its mediators the IS inﬂuences
not only the immunological defence reactions, but also exerts
detrimental eﬀects on muscle, bone, cardiac function, haemo-
poiesis and cognition [15–17]. Furthermore, the production of
chemokines (RANTES, MIP-1a, IL-8, MCP-1) is also in-
creased in the elderly, as a consequence of inﬂammation
[36]. Elevated IL6 serum levels are associated with diseases,
disability and mortality in the elderly [14,18]. Recent popula-
tion-based studies identiﬁed the magnitude of the IL-6 serum
level as a reliable marker for functional disability, and as a
predictor of disability and mortality among elderly. Some
cytokines, [37–40], for example, IL10 and TNF-a, have com-
plex and predominantly opposing roles in the inﬂammatory
responses. IL10 limits inﬂammatory responses, whereas
TNF-a increases local and systemic inﬂammatory reactions.
Interperson diﬀerences in the regulation of IL10 and TNF-
a production may be critical with respect to the ﬁnal outcome
of an inﬂammatory response. The increased production of
IL-6 and TNF-a and the reduced production of growth hor-
mone and IGF-I are directly involved in the loss of fat-free
mass during ageing. The individual genetic background and
the eventual inﬂuence of counteracting cytokines could there-
fore play a determinating role in the onset of age-related dis-
eases. Genetic variations located within the promoter regions
of pro-inﬂammatory and regulatory cytokines could inﬂuence
inﬂamm-ageing and the susceptibility to age-related diseases
[13].
In conclusion, individuals genetically equipped of strong
immunological defence mechanisms and concomitantly char-
acterized by eﬃcient mechanisms for the control of inﬂamma-
tory reactions, could be potentially destined to become healthy
centenarians [41,42]. The lifelong antigenic load and the oxida-
tive stress, impinging upon the IS, conﬁgurate the individual
immunological history. Longevity largely coincides with suc-
cessful IS remodeling in response to stressors. Healthy cente-
narians are therefore those who have the better capacity to
adapt to damaging agents and in particular to immunological
stressors.References
[1] Rea, I.M. (2004) Ageing in the 21st century. Where to and how
will we get there? Report on the 10th congress of the international
association of biomedical gerontology, the geriatricians view.
Exp. Gerontol. 39, 283–284.
[2] Franceschi, C. (2003) Continuous remodeling as a key to aging
and survival. Biogerontology 4, 329–334.
[3] Hughes, K.A., Alipaz, J.A., Drnevich, J.M. and Reynolds, R.M.
(2002) A test of evolutionary theories of aging. Proc. Natl. Acad.
Sci. 99, 14286–14291.
[4] Ginaldi, L. and Sternberg, H. (2003) The immune system in:
Physiological Basis of Aging and Geriatrics (Timiras, P.S., Ed.),
third ed, pp. 265–283, CRC Press, New York.
[5] Franceschi, C. and Bonafe`, M. (2003) Centenarians as a model for
healthy aging. Biochem. Soc. Transact. 31, 457–461.
[6] Cooper, R.S. (2003) Gene-environment interactions and the
etiology of common complex disease. Ann. Int. Med. 139, 445–
449.
[7] Hasty, P., Campisi, J., Hoeijmakers, J., vanSteeg, H. and Vijg, J.
(2003) Aging and genome maintenance: lessons from the mouse?
Science 299, 1355–1359.[8] Franceschi, C., Bonafe`, M. and Valensin, S. (2000) Human
immunosenescence: the prevailing of innate immunity, the failing
of clonotypic immunity, and the ﬁlling of immunological space.
Vaccine 18, 1717–1720.
[9] De Martinis, M., Modesti, M. and Ginaldi, L. (2004) Phenotypic
and functional changes of circulating monocytes and polymor-
phonuclear leucocytes from elderly persons. Immunol. Cell. Biol.
82, 415–420.
[10] Chung, H.Y., Kim, H.J., Kim, K.W., Choi, J.S. and Yu, B.P.
(2002) Molecular inﬂammation hypothesis of aging based on the
anti-aging mechanism of calorie restriction. Micr. Res. Tec. 59,
264–272.
[11] Zanni, F., Vescovini, R., Biasini, C., Fagnoni, F., Zanlari, L.,
Telera, A., Di Pede, P., Passeri, G., Pedrazzoni, M., Passeri, M.,
Franceschi, C. and Sansoni, P. (2003) Marked increase with age of
type 1 cytokines within memory and eﬀector/cytotoxic CD8+ T
cells in humans: a contribution to understand the relationship
between inﬂammation and immunosenescence. Exp. Gerontol. 38,
981–987.
[12] Pawelec, G., Ouyang, Q., Colonna-Romano, G., Candore, G.,
Lio, D. and Caruso, C. (2002) Is human immunosenescence
clinically relevant? Looking for immunological risk phenotypes.
Trends Immunol. 23, 330–332.
[13] Lio, D., Scola, L., Crivello, A., Colonna-Romano, G., Candore,
G., Bonafe`, M., Cavallone, L., Marchegiani, F., Olivieri, F.,
Franceschi, C. and Caruso, C. (2003) Inﬂammation, genetics, and
longevity: further studies on the protective eﬀects in men of IL-10-
1082 promoter SNP and its interaction with TNF-a-308 promoter
SNP. J. Med. Genet. 40, 296–299.
[14] Roubenoﬀ, R. (2003) Catabolism of aging: is it an inﬂammatory
process? Curr. Opin. Clin. Nutr. Metab. Care 6, 295–299.
[15] Barbieri, M., Ferrucci, L., Ragno, E., Corsi, A., Bandinelli, S.,
Bonafe`, M., Olivieri, F., Giovagnetti, S., Franceschi, C. and
Guralnik, J.M. (2003) Chronic inﬂammation and the eﬀect of
IGF-I on muscle strength and power in older persons. Am. J.
Physiol. Endocrinol. Metab. 284, 481–487.
[16] Licastro, F., Grimaldi, L.M.E., Bonafe`, M., Martina, C., Olivieri,
F., Cavallone, L., Giovagnetti, S., Masliah, E. and Franceschi, C.
(2003) Interleukin-6 gene alleles aﬀect the risk of Alzheimers
disease and levels of the cytokine in blood and brain. Neurobiol.
Aging 24, 921–926.
[17] Abbatecola, A.M., Ferrucci, L., Grella, R., Bandinelli, S., Bonafe`,
M., Barbieri, M., Corsi, A.M., Lauretani, F., Franceschi, C. and
Paolisso, G. (2004) Diverse eﬀect of inﬂammatory markers on
insulin resistance and insulin-resistance syndrome in the elderly. J.
Am. Geriatr. Soc. 52, 399–404.
[18] Roubenoﬀ, R., Parise, H., Payette, H.A., Abad, L.W., DAgos-
tino, R., Jacques, P.F., Wilson, P.W., Dinarello, C.A. and
Facchini, A. (2003) Cytokines, insulin-like growth factor 1,
sarcopenia, and mortality in very old community-dwelling men
and women: the Framingham heart study. Am. J. Med. 115, 429–
435.
[19] Appay, V. and Rowland-Jones, S.L. (2002) Premature ageing of
the immune system: the cause of AIDS?. Trends Immunol. 23,
580–585.
[20] Valenzuela, H.F. and Eﬀros, R.B. (2002) Divergent telomerase
and CD28 expression patterns in human CD4 and CD8 T cells
following repeated encounters with the same antigenic stimulus.
Clin. Immunol. 105, 117–125.
[21] Ouyang, Q., Wagner, W.M., Wikby, A., Walter, S., Aubert, G.,
Dodi, A.I., Travers, P. and Pawelec, G. (2003) Large numbers of
dysfunctional CD8+ T lymphocytes bearing receptors for a single
dominant CMV epitope in the very old. J. Clin. Immunol. 23,
247–257.
[22] Franceschi, C., Valensin, S., Bonafe`, M., Paolisso, G., Yashin,
A.I., Monti, D. and De Benedictis, G. (2000) The network and the
remodeling theories of aging: historical background and new
perspectives. Exp. Gerontol. 35, 879–896.
[23] Van Remmen, H. and Richardson, A. (2001) Oxidative damage to
mitochondria and aging. Exp. Gerontol. 36, 957–968.
[24] Ferbeyre, G. and Lowe, S.W. (2002) The price of tumour
suppression?. Nature 415, 26–27.
[25] Mattson, M.P., Duan, W., Pedersen, W.A. and Culmsee, C.
(2001) Neurodegenerative disorders and ischemic brain diseases.
Apoptosis 6, 69–81.
M. De Martinis et al. / FEBS Letters 579 (2005) 2035–2039 2039[26] Salvioli, S., Bonafe`, M., Capri, M., Monti, D. and Franceschi, C.
(2001) Mitochondria, aging and longevity – a new perspective.
FEBS Lett. 492, 9–13.
[27] Ginaldi, L., De Martinis, M., Monti, D. and Franceschi, C. (2004)
The immune system in the elderly. Activation-induced and
damage-induced apoptosis. Immunol. Res. 30, 81–94.
[28] Ginaldi, L., De Martinis, M., Monti, D. and Franceschi, C. (2005)
Chronic antigenic load and apoptosis in immunosenescence.
Trends Immunol. 26, 79–84.
[29] Cawthon, R.M., Smith, K.R., OBrien, E., Sivatchenko, A. and
Kerber, R.A. (2003) Association between telomere length in blood
andmortality in people aged 60 years or older.Lancet 361, 393–395.
[30] Saretzki, G. and Von Zglinicki, T. (2002) Replicative aging,
telomeres and oxidative stress. Ann. N.Y. Acad. Sci. 959, 24–29.
[31] Eﬀros, R.B. (2004) Replicative senescence of CD8 T cells: eﬀect
on human ageing. Exp. Gerontol. 39, 517–524.
[32] Franceschi, C., Valensin, S., Fagnoni, F., Barbi, C. and Bonafe`,
M. (1999) Biomarkers of immunosenescence within an evolution-
ary perspective: the challenge of heterogeneity and the role of
antigenic load. Exp. Gerontol. 34, 911–921.
[33] Olsson, J., Wikby, A., Johansson, B., Lofgren, S., Nilsson, B.O.
and Ferguson, F.G. (2000) Age-related change in peripheral
blood T-lymphocyte subpopulations and cytomegalovirus infec-
tion in the very old: the Swedish longitudinal OCTO immune
study. Mech. Ageing Dev. 121, 187–201.
[34] Wikby, A., Johansson, B., Olsson, J., Lofgren, S., Nilsson, B.O.
and Ferguson, F. (2002) Expansions of peripheral blood CD8 T-
lymphocyte subpopulations and an association with cytomegalo-
virus seropositivity in the elderly: the Swedish NONA immune
study. Exp. Gerontol. 37, 445–453.[35] Fagnoni, F.F., Vescovini, R., Passeri, G., Bologna, G., Pedrazz-
oni, M., Lavagetto, G, Casti, A., Franceschi, C., Passeri, M. and
Sansoni, P. (2000) Shortage of circulating naive CD8+ T cells
provides new insights on immunodeﬁciency in aging. Blood 95,
2860–2868.
[36] Mariani, E., Pulsatelli, L., Neri, S., Dolzani, P., Meneghetti, A.,
Silvestri, T., Ravaglia, G., Forti, P., Cattini, L. and Facchini, A.
(2002) RANTES and MIP-1alpha production by T lymphocytes,
monocytes and NK cells from nonagenarian subjects. Exp.
Gerontol. 37, 219–226.
[37] Brunsgaard, H., Andersen-Ranberg, K., Hjelmborg, J.B., Peder-
sen, B.K. and Jeune, B. (2003) Elevated levels of tumor necrosis
factor alpha and mortality in centenarians. Am. J. Med. 115, 278–
283.
[38] Brunsgaard, H., Ladelund, S., Pedersen, A.N., Schroll, M. and
Jorjensen, T. (2003) Predicting death from tumour necrosis
factor-alpha and interleukin-6 in 80-year-old people. Clin. Exp.
Immunol. 132, 24–31.
[39] Cappola, A.R., Xue, Q-L., Ferrucci, L., Guralnik, J.M.,
Volpato, S. and Fried, L.P. (2003) Insulin-like growth factor I
and interleukin-6 contribute synergistically to disability and
mortality in older women. J. Clin. Endocrinol. Metab. 88, 2019–
2025.
[40] Anisimov, V.N. (2003) Insulin/IGF-1 signaling pathway driving
aging and cancer as a target for pharmacological intervention.
Exp. Gerontol. 38, 1041–1049.
[41] Perls, T. and Terry, D. (2003) Understanding the determinants of
exceptional longevity. Ann Int Med. 139, 445–449.
[42] Troen, B.R. (2003) The biology of aging. Mount Sinai J. Med. 70,
3–22.
